Biotech Movers

Updated July 15, 2026

Stocks with the most signal activity right now: fund position changes, insider purchases, and upcoming catalysts from 20 specialist biotech hedge funds. Ranked by composite activity score.

How the activity score works

What counts as a mover?

Any biotech stock with recent signal activity: new or changed fund positions from the latest 13F filings, insider purchases in the last 30 days, or an upcoming catalyst within 90 days. Stocks are ranked by an activity score that weights these signals.

How often is this updated?

This page refreshes every hour. Fund position data updates quarterly after 13F filing deadlines. Insider signals are ingested daily from SEC EDGAR Form 4 filings. Catalyst dates are refreshed weekly.

What does the activity score mean?

The activity score combines the number of funds with recent position changes, insider buying activity and dollar volume, catalyst proximity, and fund convergence. Higher scores indicate more concurrent signal activity around a stock.

Are exits and trims included?

Yes. Fund exits and trims appear in the table because they are actionable signals. A multi-fund exit from a stock is just as informative as a multi-fund accumulation.

429 active tickers0 with insider buys29 catalysts in 30d

Ticker	Fund Signal	Funds↕	Insider Buys↕	Next Catalyst↕	Score?↓
PCVX Vaxcyte Inc.	Added Rock Springs Capital, Cormorant Asset Management +6	3	—	200d Ph3	150
RNA Avidity Biosciences Inc.	Exited OrbiMed Advisors, Deep Track Capital +6	4	—	47d Ph3	145
RVMD Revolution Medicines Inc.	Added Baker Bros. Advisors, Eventide Asset Management +4	3	—	304d Ph2	120
CELC Celcuity Inc.	Trimmed Eventide Asset Management, Commodore Capital +4	2	—	2d PDUFA	120
GPCR Structure Therapeutics Inc.	Trimmed Rock Springs Capital, Driehaus Capital +4	6	—	47d Ph2	115
SYK STRYKER CORP	New Rock Springs Capital, OrbiMed Advisors +4	1	—	169d Ph2	115
CNTA Centessa Pharmaceuticals plc	Trimmed Cormorant Asset Management, Avoro Capital Advisors +5	2	—	169d Ph2	110
ARGX argenx SE	Exited Perceptive Advisors, Rock Springs Capital +4	2	—	16d Ph2	110
TNGX Tango Therapeutics Inc.	Exited Baker Bros. Advisors, Deep Track Capital +4	4	—	259d Ph2	110
BEAM Beam Therapeutics Inc.	Exited EcoR1 Capital, Tang Capital Management +4	3	—	169d Ph2	110
DSGN Design Therapeutics, Inc.	Exited Cormorant Asset Management, Rock Springs Capital +4	3	—	65d Ph3	110
ETNB 89bio Inc.	Exited Rock Springs Capital, Cormorant Asset Management +4	5	—	—	105
PRAX Praxis Precision Medicines, Inc.	Added Driehaus Capital, Cormorant Asset Management +2	3	—	16d Ph3	105
AAVXF Abivax S.A.	Added OrbiMed Advisors, Cormorant Asset Management +4	2	—	169d Ph2	105
CRVS Corvus Pharmaceuticals Inc.	New Commodore Capital, Deep Track Capital +3	2	—	350d Ph2	100
JANX Janux Therapeutics Inc.	Added Deep Track Capital, OrbiMed Advisors +4	2	—	—	100
ISRG Intuitive Surgical Inc.	Exited Driehaus Capital, Eventide Asset Management +4	2	—	289d Ph3	95
VERA Vera Therapeutics Inc.	Exited Driehaus Capital, Rock Springs Capital +4	1	—	77d Ph2	95
NUVL Nuvalent Inc.	Held Driehaus Capital, Commodore Capital +3	3	—	534d Ph2	95
IRON Disc Medicine Inc.	Exited Rock Springs Capital, RA Capital Management +3	4	—	77d Ph3	95
FDMT 4D Molecular Therapeutics, Inc.	Trimmed RA Capital Management, BVF Partners +3	3	—	259d Ph2	95
AXSM Axsome Therapeutics Inc.	Trimmed Deep Track Capital, OrbiMed Advisors +3	4	—	139d Ph2	95
BPMC Blueprint Medicines Corporation	Exited Driehaus Capital, Eventide Asset Management +4	2	—	169d Ph2	95
ASND Ascendis Pharma A/S	Trimmed Rock Springs Capital, Avoro Capital Advisors +3	3	—	350d Ph3	95
IDYA IDEAYA Biosciences Inc.	Exited Cormorant Asset Management, Redmile Group +3	4	—	184d Ph3	95
EWTX Edgewise Therapeutics, Inc.	Exited EcoR1 Capital, Driehaus Capital +3	4	—	77d Ph2	95
MLTX MoonLake Immunotherapeutics	Exited EcoR1 Capital, Perceptive Advisors +4	2	—	75d Ph3	95
INSM Insmed Incorporated	Held Driehaus Capital, Rock Springs Capital +3	4	—	169d Ph3	95
VERV Verve Therapeutics Inc.	Exited Baker Bros. Advisors, EcoR1 Capital +3	3	—	—	90
BEIGF BeOne Medicines Ltd.	Added Driehaus Capital, Casdin Capital +1	3	—	16d Ph3	90
CYTK Cytokinetics Incorporated	Exited Driehaus Capital, Tang Capital Management +4	2	—	—	90
AKRO Akero Therapeutics Inc.	Exited EcoR1 Capital, OrbiMed Advisors +3	4	—	—	90
SLNO SOLENO THERAPEUTICS INC	Trimmed Commodore Capital, Avoro Capital Advisors +4	—	—	—	90
QURE uniQure N.V.	Trimmed RTW Investments, Eventide Asset Management +4	—	—	—	90
EVMN Evommune, Inc.	Added RTW Investments, Eventide Asset Management +2	—	—	16d Ph2	90
XENE Xenon Pharmaceuticals Inc.	Trimmed Rock Springs Capital, Deep Track Capital +3	2	—	47d Ph3	85
IVVD Invivyd, Inc.	Trimmed Redmile Group, OrbiMed Advisors +3	—	—	47d Ph3	85
HELP CYBIN INC.	Exited RA Capital Management, Tang Capital Management +3	1	—	47d Ph3	85
VKTX Viking Therapeutics Inc.	Exited Perceptive Advisors, Driehaus Capital +3	2	—	351d Ph3	80
IMVT Immunovant Inc.	Exited Rock Springs Capital, Cormorant Asset Management +2	3	—	108d Ph2	80
IPSC Century Therapeutics, Inc.	New Commodore Capital, Deep Track Capital +2	1	—	—	80
ALNY Alnylam Pharmaceuticals Inc.	Exited Avoro Capital Advisors, OrbiMed Advisors +2	4	—	286d Ph2	80
JAZZ Jazz Pharmaceuticals plc	Exited Driehaus Capital, Deep Track Capital +2	—	—	16d Ph3	80
RCKT Rocket Pharmaceuticals Inc.	Exited Driehaus Capital, Cormorant Asset Management +2	3	—	139d Ph3	80
CLDX Celldex Therapeutics Inc.	Trimmed Eventide Asset Management, Rock Springs Capital +3	1	—	108d Ph3	80
DMRA Damora Therapeutics, Inc.	New Commodore Capital, Avoro Capital Advisors +2	—	—	—	80
ARWR Arrowhead Pharmaceuticals Inc.	Exited Commodore Capital, Driehaus Capital +3	1	—	108d Ph2	80
SRPT Sarepta Therapeutics Inc.	Exited Deep Track Capital, RA Capital Management +3	2	—	108d Ph3	80
CRNX Crinetics Pharmaceuticals Inc.	Exited Commodore Capital, Eventide Asset Management +3	2	—	108d Ph2	80
ARVN Arvinas Inc.	Exited Commodore Capital, Tang Capital Management +3	1	—	503d Ph2	80

Showing 50 of 429

Get movers before the market opens

Fund moves, insider buys, and catalyst alerts — delivered free every Monday.

See why PCVX is active — and what comes next

AI context on every fund move, insider trade, and catalyst. Full access for 14 days. Card required, no charge until day 15. Cancel anytime.

Start 14-Day Free Trial

Drill into any signal

Fund Convergence

See which stocks multiple specialist funds are buying at once

Catalyst Calendar

Every PDUFA date, Phase 3 readout, and AdCom in one view

Insider Trading

When executives buy their own stock — the strongest bullish signal

Cash Runway

Which biotechs are running low on cash and face dilution risk

Short Squeeze

High short interest + fund buying + upcoming catalyst = squeeze setup

Signal Rankings

Every signal in one composite score — ranked by conviction

13F Changes

What top biotech funds bought and sold in the latest 13F filing

Want AI context on every signal? Start free trial →